Rapport Therapeutics Inc....

NASDAQ: RAPP · Real-Time Price · USD
10.03
-0.79 (-7.30%)
At close: May 27, 2025, 2:38 PM

Rapport Therapeutics Common Stock Statistics

Share Statistics

Rapport Therapeutics Common Stock has 36.5M shares outstanding. The number of shares has increased by 3.17% in one year.

Shares Outstanding 36.5M
Shares Change (YoY) 3.17%
Shares Change (QoQ) -0.22%
Owned by Institutions (%) 99.99%
Shares Floating n/a
Failed to Deliver (FTD) Shares 13,903
FTD / Avg. Volume 5.88%

Short Selling Information

The latest short interest is 2.52M, so 6.91% of the outstanding shares have been sold short.

Short Interest 2.52M
Short % of Shares Out 6.91%
Short % of Float 16.79%
Short Ratio (days to cover) 19.16

Valuation Ratios

The PE ratio is -46.98 and the forward PE ratio is -2.53. Rapport Therapeutics Common Stock's PEG ratio is -0.47.

PE Ratio -46.98
Forward PE -2.53
PS Ratio 0
Forward PS 16
PB Ratio 12.05
P/FCF Ratio -54.72
PEG Ratio -0.47
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Rapport Therapeutics Common Stock.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 35.34, with a Debt / Equity ratio of 0.

Current Ratio 35.34
Quick Ratio 35.34
Debt / Equity 0
Debt / EBITDA -0.02
Debt / FCF -0.02
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee n/a
Profits Per Employee $-1,134,884.06
Employee Count 69
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.11, so Rapport Therapeutics Common Stock's price volatility has been higher than the market average.

Beta 0.11
52-Week Price Change n/a
50-Day Moving Average 10.16
200-Day Moving Average 16.79
Relative Strength Index (RSI) 54.24
Average Volume (20 Days) 236,463

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -83.06M
Net Income -78.31M
EBITDA -77.47M
EBIT -78.31M
Earnings Per Share (EPS) -0.38
Full Income Statement

Balance Sheet

The company has 56.8M in cash and 1.48M in debt, giving a net cash position of 55.33M.

Cash & Cash Equivalents 56.8M
Total Debt 1.48M
Net Cash 55.33M
Retained Earnings -123.75M
Total Assets 302.05M
Working Capital 281.58M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -64.83M and capital expenditures -2.4M, giving a free cash flow of -67.23M.

Operating Cash Flow -64.83M
Capital Expenditures -2.4M
Free Cash Flow -67.23M
FCF Per Share -0.32
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

RAPP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for RAPP is $35, which is 223.5% higher than the current price. The consensus rating is "Buy".

Price Target $35
Price Target Difference 223.5%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score 12.78
Piotroski F-Score 2